Statements in which the resource exists.
SubjectPredicateObjectContext
http://www.reactome.org/bio...rdf:typebiopax3:BiochemicalReactionlld:biopax3
http://www.reactome.org/bio...biopax3:commentEdited: Rothfels, K, 2012-05-16lld:biopax3
http://www.reactome.org/bio...biopax3:commentReviewed: Ezzat, S, 2012-05-15lld:biopax3
http://www.reactome.org/bio...biopax3:commentAuthored: Rothfels, K, 2012-02-09lld:biopax3
http://www.reactome.org/bio...biopax3:commentFP-1039 is a soluble fusion protein consisting of the extracellular region of FGFR1c bound to the Fc region of human IgG1. It is capable of binding to a wide range of FGF ligands and thereby prevents activation of multiple FGF receptors. FP-1039 is in Phase I clinical trials in solid malignancies and in Phase II trials for patients with endometrial cancers harbouring the activating mutations S252W and P253R (reviewed in Wesche, 2011).lld:biopax3
http://www.reactome.org/bio...biopax3:xrefhttp://identifiers.org/pubm...lld:biopax3
http://www.reactome.org/bio...biopax3:xrefurn:biopax:UnificationXref:...lld:biopax3
http://www.reactome.org/bio...biopax3:xrefurn:biopax:UnificationXref:...lld:biopax3
http://www.reactome.org/bio...biopax3:dataSourceurn:biopax:Provenance:react...lld:biopax3
http://www.reactome.org/bio...biopax3:dataSourcehttp://www.reactome.org/bio...lld:biopax3
http://www.reactome.org/bio...biopax3:displayNameFP-1039 acts as a ligand-trap for FGFR2b-binding ligands in endometrial cancerlld:biopax3
http://www.reactome.org/bio...biopax3:lefthttp://www.reactome.org/bio...lld:biopax3
http://www.reactome.org/bio...biopax3:lefthttp://www.reactome.org/bio...lld:biopax3
http://www.reactome.org/bio...biopax3:righthttp://www.reactome.org/bio...lld:biopax3
http://www.reactome.org/bio...biopax3:stepProcesshttp://www.reactome.org/bio...lld:biopax3
http://www.reactome.org/bio...biopax3:pathwayComponenthttp://www.reactome.org/bio...lld:biopax3